{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:58:22Z","timestamp":1792979902561,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-12050-7","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T09:44:13Z","timestamp":1766569453000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety and efficacy of BIC\/FIC\/TAF in older PLHIV: impact on bone density, renal function, and lipid profiles in a real-world Chinese cohort"],"prefix":"10.1186","volume":"25","author":[{"given":"Chengyu","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yining","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinlan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyuan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiju","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"12050_CR1","unstructured":"The path that ends aids. Available from: https:\/\/thepath.unaids.org\/wp-content\/themes\/unaids2023\/assets\/files\/2023_report.pdf."},{"key":"12050_CR2","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1111\/hiv.13591","volume":"24","author":"JM Trevillyan","year":"2023","unstructured":"Trevillyan JM, Behrens G. Ageing with HIV; a victory, a challenge and a call to action. HIV Med. 2023, Dec;24:1169\u201371. https:\/\/doi.org\/10.1111\/hiv.13591. Epub 2023 Nov 22.","journal-title":"HIV Med"},{"key":"12050_CR3","doi-asserted-by":"publisher","first-page":"388","DOI":"10.2174\/1570162X18666200609115615","volume":"18","author":"D Vargas-Pacherrez","year":"2020","unstructured":"Vargas-Pacherrez D, Cotrim HP, Pires L, Cunha V, Coelho V, Brites C, et al. MetabolicyndromeinHIV-patients in ntiretroviral herapy. Curr HIV Res. 2020;18:388\u201395. https:\/\/doi.org\/10.2174\/1570162X18666200609115615.","journal-title":"Curr HIV Res"},{"key":"12050_CR4","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S1474-4422(21)00252-0","volume":"20","author":"GBD","year":"2021","unstructured":"GBD. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the global burden of disease study 2019. Lancet Neurol Oct. 2021;20:795\u2013820. https:\/\/doi.org\/10.1016\/S1474-4422(21)00252-0. Epub 2021 Sep 3.","journal-title":"Lancet Neurol Oct"},{"key":"12050_CR5","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.bjid.2013.05.009","volume":"17","author":"OA Ayd\u0131n","year":"2013","unstructured":"Ayd\u0131n OA, Karaosmanoglu HK, Karahasanoglu R, Tahmaz M, Nazl\u0131can O. Prevalence and risk factors ofosteopenia\/osteoporosisin TurkishHIV\/AIDS patients. Braz J Infect Dis. 2013, Nov-Dec;17:707\u201311. https:\/\/doi.org\/10.1016\/j.bjid.2013.05.009. Epub 2013 Sep 25.","journal-title":"Braz J Infect Dis"},{"key":"12050_CR6","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1007\/s00415-017-8503-2","volume":"264","author":"C Eggers","year":"2017","unstructured":"Eggers C, Arendt G, Hahn K, Husstedt IW, Maschke M, Neuen-Jacob E, et al. HIV-1-associated neurocognitive disorder: epidemiology, pathogenesis, diagnosis, and treatment. J Neurol. 2017, Aug;264:1715\u201327. https:\/\/doi.org\/10.1007\/s00415-017-8503-2. Epub 2017 May 31.","journal-title":"J Neurol"},{"key":"12050_CR7","doi-asserted-by":"publisher","first-page":"24353","DOI":"10.1038\/s41598-021-03672-3","volume":"11","author":"F Wang","year":"2021","unstructured":"Wang F, Xiang P, Zhao H, Gao G, Yang D, Xiao J, et al. A retrospective study of distribution of HIV associated malignancies among inpatients from 2007 to 2020 in China. Sci Rep. 2021, Dec, 21;11:24353. https:\/\/doi.org\/10.1038\/s41598-021-03672-3.","journal-title":"Sci Rep"},{"key":"12050_CR8","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1007\/s11606-013-2449-6","volume":"28","author":"C Holtzman","year":"2013","unstructured":"Holtzman C, Armon C, Tedaldi E, Chmiel JS, Buchacz K, Wood K, et al. Polypharmacy and risk of antiretroviral drug interactions among the aging HIV-infected population. J Gen Intern Med. 2013, Oct;28:1302\u201310. https:\/\/doi.org\/10.1007\/s11606-013-2449-6. Epub 2013 Apr 20.","journal-title":"J Gen Intern Med"},{"key":"12050_CR9","unstructured":"Acquired Immunodeficiency Syndrome and Hepatitis C Professional Group. Society of infectious diseases, Chinese medical association, Chinese center for disease control and prevention. Chinese guidelines for diagnosis and treatment of human immunodeficiency virus infection\/acquired immunodeficiency syndrome. 2024ed."},{"key":"12050_CR10","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s40121-021-00419-5","volume":"10","author":"F Maggiolo","year":"2021","unstructured":"Maggiolo F, Rizzardini G, Molina JM, Pulido F, De Wit S, Vandekerckhove L, et al. Bictegravir\/emtricitabine\/tenofovir alafenamide in Virologically Suppressed People with HIV aged 65 years: week 48 results of a phase 3b, open-label trial. Infect Dis Ther. 2021, Jun;10:775\u201388. https:\/\/doi.org\/10.1007\/s40121-021-00419-5. Epub 2021 Mar 9.","journal-title":"Infect Dis Ther"},{"key":"12050_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/hiv.13319","volume":"24","author":"F Maggiolo","year":"2023","unstructured":"Maggiolo F, Rizzardini G, Molina JM, Pulido F, De Wit S, Vandekerckhove L, et al. Bictegravir\/emtricitabine\/tenofovir alafenamide in older individuals with HIV: esults of a 96-week,phase3b,open-label, switchtrialin virologically suppressed people 65 years of age. HIV Med. 2023, Jan;24:27\u201336. https:\/\/doi.org\/10.1111\/hiv.13319. Epub 2022 May 8.","journal-title":"HIV Med"},{"key":"12050_CR12","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/clpt.2011.58","volume":"89","author":"GP Aithal","year":"2011","unstructured":"Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89:806\u201315. https:\/\/doi.org\/10.1038\/clpt.2011.58.","journal-title":"Clin Pharmacol Ther"},{"key":"12050_CR13","doi-asserted-by":"publisher","first-page":"902","DOI":"10.3760\/cma.j.cn112138-20221013-00755","volume":"8","author":"Kidney disease prevention and control professional committee of the chinese association of preventive medicine","year":"2023","unstructured":"Kidney disease prevention and control professional committee of the chinese association of preventive medicine. Guidelines for the early evaluation and management of chronic Kidney disease in China. Chin J Intern Med. 2023;8:902\u201330. https:\/\/doi.org\/10.3760\/cma.j.cn112138-20221013-00755. (in Chinese).","journal-title":"Chin J Intern Med"},{"key":"12050_CR14","doi-asserted-by":"publisher","unstructured":"Chinese medical association. The guideline for prevention and treatment of hyperlipidemia in Chinese adults. Chin J cardiovasc Dis. 2007 3758.2007, 05.003;35:390\u2013409. https:\/\/doi.org\/10.3760\/j.issn:0253. (in Chinese).","DOI":"10.3760\/j.issn:0253"},{"key":"12050_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12879-023-08906-5","volume":"24","author":"X Lao","year":"2024","unstructured":"Lao X, Zhang H, Deng M, Li Q, Xiao Q, He L, et al. Incidence of low-level viremia and its impact on virologic failure among people living with HIV who started an integrase strand transfer inhibitors: a longitudinal cohort study. BMC Infect Dis. 2024, Jan, 2;24:8. https:\/\/doi.org\/10.1186\/s12879-023-08906-5.","journal-title":"BMC Infect Dis"},{"issue":"8","key":"12050_CR16","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1111\/hiv.13493","volume":"24","author":"R Nasreddine","year":"2023","unstructured":"Nasreddine R, Florence E, Yombi JC, Henrard S, Darcis G, Van Praet J, et al. Belgian research on AIDS and HIV consortium (BREACH). Efficacy, durability, and tolerability of bictegravir\/emtricitabine\/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium. HIV Med. 2023, Aug;24(8):914\u201324. https:\/\/doi.org\/10.1111\/hiv.13493. Epub 2023 Apr 10.","journal-title":"HIV Med"},{"key":"12050_CR17","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s11904-012-0124-x","volume":"9","author":"K Samaras","year":"2012","unstructured":"Samaras K. The burden of diabetes andhyperlipidemiain treatedHivinfection and approaches for cardiometabolic care. Curr HIV AIDS Rep. 2012, Sep;9:206\u201317. https:\/\/doi.org\/10.1007\/s11904-012-0124-x.","journal-title":"Curr HIV AIDS Rep"},{"key":"12050_CR18","doi-asserted-by":"publisher","unstructured":"Swanepoel CR, Atta MG, D\u2019Agati VD, Estrella MM, Fogo AB, Naicker S, et al. Kidneydisease in the setting ofHivinfection: conclusions from aKidneydisease: mproving global outcomes (KDIGO) controversies conference. Kidney Int; Conference Participants. 2018 Mar:545\u201359. https:\/\/doi.org\/10.1016\/j.kint.2017.11.007. Epub 2018 Feb 3;93.","DOI":"10.1016\/j.kint.2017.11.007"},{"key":"12050_CR19","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1080\/21505594.2016.1195536","volume":"8","author":"V Appay","year":"2017","unstructured":"Appay V, Sauce D. Assessing immuneaginginHIV-infected patients. Virulence. 2017, Jul, 4;8:529\u201338. https:\/\/doi.org\/10.1080\/21505594.2016.1195536. Epub 2016 Jun 16.","journal-title":"Virulence"},{"issue":"9","key":"12050_CR20","doi-asserted-by":"publisher","first-page":"e105653","DOI":"10.1371\/journal.pone.0105653","volume":"9","author":"DA Patel","year":"2014","unstructured":"Patel DA, Snedecor SJ, Tang WY, Sudharshan L, Lim JW, Cuffe R, et al. 48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis. PLoS One. 2014, Sep, 4;9(9):e105653. https:\/\/doi.org\/10.1371\/journal.pone.0105653.","journal-title":"PLoS One"},{"key":"12050_CR21","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1097\/CM9.0000000000002939","volume":"136","author":"J Xiao","year":"2023","unstructured":"Xiao J, Gao G, Ding Y, Li J, Gao C, Xu Q, et al. Reasons, safety and efficacy analysis for conversion of HAART to TAF\/FTC\/BIC among HIV-infected patients. Chin Med J (ENGL). 2023, Dec, 20;136:2931\u201337. https:\/\/doi.org\/10.1097\/CM9.0000000000002939. Epub 2023 Nov 29.","journal-title":"Chin Med J (ENGL)"},{"key":"12050_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ijid.2022.11.012","volume":"126","author":"MS Tsai","year":"2023","unstructured":"Tsai MS, Sun HY, Chen CP, Lee CH, Lee CY, Liu CE, et al. Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N\/R mutation. Int J Infect Dis. 2023, Jan;126:39\u201347. https:\/\/doi.org\/10.1016\/j.ijid.2022.11.012. Epub 2022 Nov 13.","journal-title":"Int J Infect Dis"},{"key":"12050_CR23","unstructured":"Hoffmann C, Rockstroh JK, editors. Medizin Fokus Verlag. 2023. p. HIVBOOKp. 2023."},{"key":"12050_CR24","doi-asserted-by":"publisher","first-page":"e389","DOI":"10.1016\/S2352-3018(20)30099-0","volume":"7","author":"C Orkin","year":"2020","unstructured":"Orkin C, DeJesus E, Sax PE, Arribas JR, Gupta SK, Martorell C, et al. GS-US-380-1489; GS-US-380-1490 study investigators. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non- inferiority trials. Lancet HIV. 2020;7:e389\u2013400. https:\/\/doi.org\/10.1016\/S2352-3018(20)30099-0.","journal-title":"Lancet HIV"},{"key":"12050_CR25","doi-asserted-by":"publisher","first-page":"e27330","DOI":"10.1097\/MD.0000000000027330","volume":"100","author":"CP Rolle","year":"2021","unstructured":"Rolle CP, Nguyen V, Patel K, Cruz D, DeJesus E, Hinestrosa F. Real-world efficacy and safety of switching to bictegravir\/emtricitabine\/tenofovir alafenamide in older people living with HIV. Med (BALTIM). 2021, Sep, 24;100:e27330. https:\/\/doi.org\/10.1097\/MD.0000000000027330.","journal-title":"Med (BALTIM)"},{"issue":"1S Suppl 1","key":"12050_CR26","doi-asserted-by":"publisher","first-page":"e992","DOI":"10.1097\/MEG.0000000000001977","volume":"33","author":"M Atef","year":"2021","unstructured":"Atef M, Zayed N, Salama R, Abdel Alem S, Yousof H, Saber M, et al. Is urinary \u03b22-microglobulin a reliable marker for assessment of renal tubular dysfunction in chronic hepatitis B patients receiving tenofovir therapy? Eur J Gastroenterol Hepatol. 2021, Dec, 1;33(1S Suppl 1):e992\u201398. https:\/\/doi.org\/10.1097\/MEG.0000000000001977.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5","key":"12050_CR27","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1053\/j.ajkd.2021.03.026","volume":"78","author":"JH Ix","year":"2021","unstructured":"Ix JH, Shlipak MG. The promise of tubule biomarkers in kidney disease: a review. Am J Kidney Dis. 2021, Nov;78(5):719\u201327. https:\/\/doi.org\/10.1053\/j.ajkd.2021.03.026. Epub 2021 May 27.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"12050_CR28","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1515\/CCLM.2006.050","volume":"44","author":"M Conti","year":"2006","unstructured":"Conti M, Moutereau S, Zater M, Lallali K, Durrbach A, Manivet P, et al. Urinary cystatin C as a specific marker of tubular dysfunction. Clin Chem Lab Med. 2006;44(3):288\u201391. https:\/\/doi.org\/10.1515\/CCLM.2006.050.","journal-title":"Clin Chem Lab Med"},{"key":"12050_CR29","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1097\/QAD.0000000000002223","volume":"33","author":"SK Gupta","year":"2019","unstructured":"Gupta SK, Post FA, Arribas JR, Jj E Jr., Wohl DA, Clarke AE, et al. Renalsafety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. Aids. 2019, Jul, 15;33:1455\u201365. https:\/\/doi.org\/10.1097\/QAD.0000000000002223.","journal-title":"Aids"},{"key":"12050_CR30","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1177\/09564624221130129","volume":"33","author":"J Chang","year":"2022","unstructured":"Chang J, Do D, Delgado H, Kanimian N, Huynh A. A retrospective analysis ofboneloss intenofovir emtricitabine therapy forHivprep. Int J STD AIDS. 2022, Dec;33:1183\u201392. https:\/\/doi.org\/10.1177\/09564624221130129. Epub 2022 Oct 11.","journal-title":"Int J STD AIDS"},{"key":"12050_CR31","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ijid.2020.01.035","volume":"93","author":"X Tao","year":"2020","unstructured":"Tao X, Lu Y, Zhou Y, Zhang L, Chen Y. Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: a meta-analysis of randomized controlled trials. Int J Infect Dis. 2020, Apr;93:108\u201317. https:\/\/doi.org\/10.1016\/j.ijid.2020.01.035. Epub 2020 Jan 25.","journal-title":"Int J Infect Dis"},{"key":"12050_CR32","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/hiv.13061","volume":"22","author":"N Kanda","year":"2021","unstructured":"Kanda N, Okamoto K, Okumura H, Mieno M, Sakashita K, Sasahara T, et al. Outcomes associated with treatment change from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-1-infected patients: a real-world study in Japan. HIV Med. 2021, Jul;22:457\u201366. https:\/\/doi.org\/10.1111\/hiv.13061. Epub 2021 Mar 15.","journal-title":"HIV Med"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12050-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-12050-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12050-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T09:44:15Z","timestamp":1766569455000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-025-12050-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12050"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-12050-7","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"9 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in strict compliance with the Declaration of Helsinki. The retrospective study was conducted at Beijing Ditan Hospital and the medical ethics committee approved the study protocol and waived the requirement for informed consent due to the anonymous use of retrospective clinical data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1733"}}